2. Academic Validation
  3. Research progress of multi-target HDAC inhibitors blocking the BRD4-LIFR-JAK1-STAT3 signaling pathway in the treatment of cancer

Research progress of multi-target HDAC inhibitors blocking the BRD4-LIFR-JAK1-STAT3 signaling pathway in the treatment of cancer

  • Bioorg Med Chem. 2024 Aug 1:110:117827. doi: 10.1016/j.bmc.2024.117827.
Shuting Jia 1,  Yuye Jia 1,  Sufang Liang 1,  Liqiang Wu 2
Affiliations

Affiliations

  • 1 Jincheng People's Hospital, Jincheng 048026, China.
  • 2 School of Pharmacy, Xinxiang Medical University, Xinxiang 453003, China. Electronic address: wliq1974@163.com.
PMID: 38964169 DOI: 10.1016/j.bmc.2024.117827
Abstract

Histone deacetylase inhibitors (HDACis) show beneficial effects on different hematological malignancy subtypes. However, their impacts on treating solid tumors are still limited due to diverse resistance mechanisms. Recent studies have found that the feedback activation of BRD4-LIFR-JAK1-STAT3 pathway after HDACi incubation is a vital mechanism inducing resistance of specific solid tumor cells to HDACis. This review summarizes the recent development of multi-target HDACis that can concurrently block BRD4-LIFR-JAK1-STAT3 pathway. Moreover, our findings hope to shed novel lights on developing novel multi-target HDACis with reduced BRD4-LIFR-JAK1-STAT3-mediated drug resistance in some tumors.

Keywords

BRD4-LIFR-JAK1-STAT3; Cancer therapy; HDACis; Multi-target; Synergistic effect.

Figures